Mentioned in

References in periodicals archive

Study patients were classified into groups as follows: 1) healthy subjects without glaucoma (WG); 2) glaucoma suspected group (GSG); 3) primary open-angle glaucoma (POAG); 4) primary angle-closure glaucoma (PACG); and 5) secondary glaucoma (SG).

Prevalence of pseudoexfoliation syndrome and pseudoexfoliation glaucoma in population of north-west Croatia aged 40 and over

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

"Open-Angle Glaucoma - Pipeline Review, H2 2015" Published

Richards, PhD, director of the glaucoma research center at the University of Michigan in Ann Arbor, and coauthors examined metformin use and the risk of open-angle glaucoma (OAG) using data from a large US managed care network from 2001 through 2010.

Metformin may reduce glaucoma risk

* Trabeculoplasty, which opens the drainage canals of the eye in patients with open-angle glaucoma.

Early diagnosis, treatment can limit vision loss from glaucoma: glaucoma is detectable during an eye exam, and the most common form usually responds well to medication

One potential explanation for this significant association of Central Retinal vein occlusion (CRVO) and PEX is the secondary open-angle glaucoma caused by PEX and the higher levels of IOP associated with PEX compared to simple glaucoma as known risk factors for CRVO.

Epidemiological aspects of pseudoexfoliation syndrome: a study

Over an average of 9.7 years of follow-up, 108 participants developed open-angle glaucoma. Those who developed the condition were significantly older; more often had high myopia (severe nearsightedness) and were more often male, compared with those who did not.

Obese women may be less likely to develop chronic eye disease

Eligible patients were aged 40 years and older, did not have primary open-angle glaucoma (POAG) at baseline, and underwent eye examinations during follow-up.

Women with higher BMI at lower risk for glaucoma

* Age: For every year someone ages, their chance of progressing increases by 4%, confirming that open-angle glaucoma is primarily age-related.

Results of 15-year Canadian study on glaucoma are released

LUMIGAN(TM) ophthalmic solution received FDA approval on March 16, 2001 and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.

STUDY SHOWS LUMIGAN MORE EFFECTIVE THAN XALATAN

The Rogers family suffers from a rare subtype of primary open-angle glaucoma. As in other forms of glaucoma, the fluid in the eye doesn't drain properly.

Light at the end of the tunnel: visionary research probes the genesis of glaucoma

30, 2019 (HealthDay News) -- Netarsudil ophthalmic solution (0.02 percent; once daily) significantly reduced mean intraocular pressure (IOP) among patients with open-angle glaucoma or ocular hypertension, according to a study published in the August issue of the American Journal of Ophthalmology.

Netarsudil Lowers IOP in Glaucoma, Ocular Hypertension; ROCKET-4 study shows once-daily netarsudil noninferior to twice-daily timolol

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

Aerie Pharmaceuticals Names Vargas as Medical Director, Medical Affairs